Diagnosing malignant melanoma in ambulatory care: a systematic review of clinical prediction rules. by Harrington, Emma et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
General Practice Articles Department of General Practice
6-3-2017
Diagnosing malignant melanoma in ambulatory
care: a systematic review of clinical prediction rules.
Emma Harrington
Royal College of Surgeons in Ireland, emmaharrington@rcsi.ie
Barbara Clyne
Royal College of Surgeons in Ireland, barbaraclyne@rcsi.ie
Nieneke Wesseling
Radboud University Nijmegen
Harkiran Sandhu
Royal College of Surgeons in Ireland, harkiransandhu@rcsi.ie
Laura Armstrong
Royal College of Surgeons in Ireland, lauraarmstrong@rcsi.ie
See next page for additional authors
This Article is brought to you for free and open access by the Department
of General Practice at e-publications@RCSI. It has been accepted for
inclusion in General Practice Articles by an authorized administrator of e-
publications@RCSI. For more information, please contact epubs@rcsi.ie.
Citation
Harrington E, Clyne B, Wesseling N, Sandhu H, Armstrong L, Bennett H, Fahey T. Diagnosing malignant melanoma in ambulatory
care: a systematic review of clinical prediction rules. BMJ Open. 2017;7(3):e014096s.
Authors
Emma Harrington, Barbara Clyne, Nieneke Wesseling, Harkiran Sandhu, Laura Armstrong, Holly Bennett,
and Tom Fahey
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/gpart/112
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/gpart/112
Diagnosing malignant melanoma
in ambulatory care: a systematic review
of clinical prediction rules
Emma Harrington,1 Barbara Clyne,1 Nieneke Wesseling,2 Harkiran Sandhu,1
Laura Armstrong,1 Holly Bennett,1 Tom Fahey1
To cite: Harrington E,
Clyne B, Wesseling N, et al.
Diagnosing malignant
melanoma in ambulatory
care: a systematic review of
clinical prediction rules. BMJ
Open 2017;7:e014096.
doi:10.1136/bmjopen-2016-
014096
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
014096).
Received 30 August 2016
Accepted 10 January 2017
1HRB Centre for Primary Care
Research, Royal College of
Surgeons in Ireland, Dublin
2, Ireland
2Medical School, Radboud
University, Nijmegen,
Netherlands
Correspondence to
Dr Barbara Clyne;
barbaraclyne@rcsi.ie
ABSTRACT
Objectives: Malignant melanoma has high morbidity
and mortality rates. Early diagnosis improves
prognosis. Clinical prediction rules (CPRs) can be used
to stratify patients with symptoms of suspected
malignant melanoma to improve early diagnosis. We
conducted a systematic review of CPRs for melanoma
diagnosis in ambulatory care.
Design: Systematic review.
Data sources: A comprehensive search of PubMed,
EMBASE, PROSPERO, CINAHL, the Cochrane Library
and SCOPUS was conducted in May 2015, using
combinations of keywords and medical subject
headings (MeSH) terms.
Study selection and data extraction: Studies
deriving and validating, validating or assessing the
impact of a CPR for predicting melanoma diagnosis in
ambulatory care were included. Data extraction and
methodological quality assessment were guided by the
CHARMS checklist.
Results: From 16 334 studies reviewed, 51 were
included, validating the performance of 24 unique
CPRs. Three impact analysis studies were identified.
Five studies were set in primary care. The most
commonly evaluated CPRs were the ABCD, more than
one or uneven distribution of Colour, or a large
(greater than 6 mm) Diameter (ABCD) dermoscopy
rule (at a cut-point of >4.75; 8 studies; pooled
sensitivity 0.85, 95% CI 0.73 to 0.93, specificity 0.72,
95% CI 0.65 to 0.78) and the 7-point dermoscopy
checklist (at a cut-point of ≥1 recommending
ruling in melanoma; 11 studies; pooled sensitivity
0.77, 95% CI 0.61 to 0.88, specificity 0.80, 95%
CI 0.59 to 0.92). The methodological quality of
studies varied.
Conclusions: At their recommended cut-points, the
ABCD dermoscopy rule is more useful for ruling out
melanoma than the 7-point dermoscopy checklist.
A focus on impact analysis will help translate
melanoma risk prediction rules into useful tools for
clinical practice.
INTRODUCTION
The incidence of malignant melanoma in
most developed countries has been steadily
rising (faster than other cancer types) in
recent decades.1 2 Increases in the
age-standardised incidence of at least 4–6%
per annum have been reported internationally
in many fair-skinned populations including
Australia, the USA and most of Europe.3–5
Simultaneously, there has been a signiﬁcant
rise in overall 5-year survival in melanoma
patients, largely attributable to earlier detec-
tion and diagnosis of thinner tumours.6 While
the majority of patients may survive melanoma,
the disease has a signiﬁcant impact on patient
quality of life7 and healthcare expenditure,
with the average annual total treatment costs
for melanoma in the USA increasing to US
$3.3 billion in 2011.8 Melanoma is potentially
preventable since a signiﬁcant risk factor,
Strengths and limitations of this study
▪ The main strengths of this review are the use of
broad inclusion criteria, the systematic search of
multiple databases not limited by language, use
of the CHARMS checklist to assess methodo-
logical quality, pooling data from a broad range
of studies to enhance generalisability and the
use of a broad definition of primary care to
account for the variation in primary care services
and access internationally. Quality assessment
criteria were used to assess risk of bias and the
majority of studies were at low risk in relation to
the randomisation procedure and monitoring of
loss to follow-up.
▪ A large proportion of studies did not provide suf-
ficient information and data to perform stratified
meta-analysis according to different levels of
risk.
▪ Current research shows that dermoscopic clinical
prediction rules (CPRs) may be a useful tool for
primary care physicians prioritising appropriate
referrals for higher risk patients and adopting a
watchful waiting strategy in lower risk patients
but future impact analysis research is necessary
to establish their impact on patient outcomes.
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exposure to ultraviolet (UV) radiation, is modiﬁable.9
However, other risk factors (eg, number naevi, eye and
hair colour, freckles, familial history and genetic predispos-
ition) also play an important role in the risk of developing
melanoma.10 11
Early detection followed by curative surgery greatly
improves melanoma prognosis. However, early detection
may be affected by the challenging natures of differen-
tial diagnosis of pigmented lesions. Particularly in
primary care where the evaluation of suspected skin
lesions is imposing an increasing burden due to rising
incidences of skin cancer.12 It has been suggested that
primary care practitioners’ skills of diagnosing skin
lesions could be improved.13 A number of clinical pre-
diction pules (CPRs) and computer-assisted diagnostic
tools have been developed to assist in distinguishing
malignant melanoma from benign pigmented skin
lesions. The UK National Institute for Clinical
Excellence (NICE) guidelines advise against routine use
of computer-assisted diagnostic tools in the initial evalu-
ation of a pigmented skin lesion (NICE guidelines) and
promote use of the weighted 7-point checklist in
primary care to guide referral (NG12). When used by
dermatologists for the diagnosis of melanoma, certain
CPRs have demonstrated high sensitivity and speciﬁcity.6
Although each CPR has its own unique elements, there
is signiﬁcant overlap in terms of their content (see
online supplementary appendix 1), and while their use
is promoted, it is unclear which rules are most suitable
for use in primary care.
CPRs may be for use in clinical (ie, naked eye) exam-
ination, or in conjunction with dermoscopy.
Dermoscopy, dermatoscopy or epiluminescent micros-
copy refers to the examination of pigmented skin lesions
using surface microscopy.14 15 The use of dermoscopy,
primarily by dermatologists, has been found to increase
diagnostic accuracy compared with naked-eye inspection,
as it allows the visualisation of features that are not
visible to the naked eye.14–16 However, the effectiveness
of dermoscopy depends on clinical experience and
training. Dermatologists with formal training in dermo-
scopy have higher melanoma detection rates compared
with untrained dermatologists and primary care physi-
cians.16–18
As primary care or ambulatory care physicians are fre-
quently and increasingly confronted with the care of
skin lesions suspected of malignancy,12 it is essential to
identify tools to aid primary care practitioners to differ-
entiate patients with clinically signiﬁcant lesions, requir-
ing referral, from those who can be treated and
monitored in primary care. The aim of this study was to
perform a systematic review of CPRs for the diagnosis of
malignant melanoma, to evaluate their diagnostic accur-
acy in primary care and specialist outpatient settings,
among patients with a pigmented skin lesion. Secondary
aims were to review studies that have examined the
implementation of CPRs in clinical practice through
impact analysis studies.
METHODS
The protocol for this systematic review was published on
PROSPERO (CRD42015020898) and was conducted
according to Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.19
Search strategy and data sources
A systematic literature search was conducted (May 2015)
including the following databases: PubMed, EMBASE,
PROSPERO, CINAHL, the Cochrane Library and
SCOPUS, using combinations of the following keywords
and MeSH terms: melanoma/diagnosis, melanoma, pre-
diction, score, model, decision, sensitivity, speciﬁcity, val-
idate, derived. Hand searches of references of retrieved
full-text articles and key author searches supplemented
the search. No date or language limits were imposed.
Study selection
All articles were initially screened for inclusion accord-
ing to title and abstract by two reviewers (NW, EH).
Full-text articles of studies considered eligible for inclu-
sion were independently read by both reviewers, with
any disagreements resolved by a third reviewer (BC).
Validation studies
Validation studies were eligible for inclusion if they met
the following criteria;
1. Population: Adults (age ≥18 years) with a pigmented
skin lesion in ambulatory care settings in general
practice/family medicine, dermatology, plastic
surgery and other relevant specialties.
2. Risk: Derivation and/or validation of a CPR for mel-
anoma diagnosis to aid decision making about refer-
ral or investigation of a pigmented skin lesion. CPRs
were deﬁned as ‘a clinical tool that quantiﬁes the
individual contributions that various components of
the history, physical examination and investigations
make toward the diagnosis, prognosis or likely
response to treatment in a patient’.
3. Comparison: Usual clinical judgement for decision
making about referral or investigation OR another
CPR for melanoma diagnosis.
4. Primary outcome: Performance of a CPR for predicting
diagnosis of malignant melanoma (in terms of sensi-
tivity, speciﬁcity, negative predictive values and posi-
tive predictive values).
Observational study designs (eg, cohort, cross-
sectional, case–control) were included. Studies were
excluded where they had undergone derivation only,
reported individual predictors only, or used computer-
assisted diagnostic tools, following the NICE guideline
recommendation against the routine use of computer-
assisted diagnostic tools.20
Impact analysis
The following study designs were included for impact
analysis: (cluster) randomised controlled trials (RCTs),
controlled before–after studies or interrupted time series
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studies. We excluded uncontrolled study designs. We
included studies where a melanoma CPR was used to
predict melanoma compared with usual care in the clin-
ical setting. The outcomes of interest included physician
behaviour, process of care, patient outcomes and/or
cost-effectiveness. A requirement for inclusion was that
the CPR comprised the entire intervention. Studies
where the CPR was implemented as part of a broader
guideline, protocol or decision aid were excluded.
Studies that used a CPR to determine eligibility for trial
inclusion but were not part of the intervention were also
excluded.
Data extraction
Data were extracted by four reviewers (LA, HB, HS, EH)
using a data form based on the CHARMS checklist.21
Data extracted included study design and setting,
patient demographics and inclusion criteria, CPR name,
CPR type (clinical or dermoscopic), predictive accuracy
of the CPR (sensitivity/speciﬁcity) and for impact ana-
lysis, the impact on the primary outcome.
Critical appraisal of studies
Two reviewers (EH, NW) critically appraised included
studies using the CHARMS checklist, developed to
provide guidance on data extraction and critical
appraisal of prediction modelling studies.21 The check-
list contains 11 domains of critical appraisal. The meth-
odological quality of each study was independently
evaluated by two reviewers and by a third reviewer if con-
sensus was not reached. The methodological quality of
each impact analysis study was also independently
assessed, using an appropriate quality assessment check-
list. RCTs were assessed using the Cochrane risk of bias
tool and controlled before–after studies were evaluated
using Cochrane criteria for these study designs.22
Statistical analysis
Statistical analysis was conducted using Stata V.12
(StataCorp, College Station, Texas, USA), in particular
the metandi and midas commands. For each CPR, a
standard cut-point was identiﬁed (table 1). From each
included study we extracted (where available) the
Table 1 CPRs identified for inclusion with cut-points for identification of melanoma
Rule name Cut-point used
Number of validation
studies
Clinical rule
ABCDE clinical rule ≥1 or ≥2 4
ABCD clinical rule ≥1 4
Revised 7-point checklist (clinical) ≥3 4
7-point checklist (clinical) ≥3 4
Dermoscopic rules
ABCD rule of dermoscopy* ≥4.75 15
≥5.45 6
≥4.2 1
Not reported 1
7-point checklist for dermoscopy ≥3 17
Menzies 1996 dermoscopy for melanoma ≥1, no negative features 8
3-point checklist for dermoscopy ≥1 6
Seven features for melanoma (7FFM) ≥2 5
CASH dermoscopy algorithm ≥8 3
ABCDE rule (dermoscopy) Not reported 2
The 3-colour dermoscopy test ≥3 2
Revised 7-point checklist for dermoscopy ≥1 1
Kreusch 1992 dermoscopy Not reported 1
Nilles 1994 dermoscopy Not reported 1
Menzies 2008 dermoscopy for melanoma ≥1 1
DynaMel algorithm ≥3 1
Menzies 2008 dermoscopy for skin cancer ≥0 (high sensitivity); ≥1 (high specificity) 1
Simplified ABC-point list for dermoscopy ≥4 1
AC rule for dermoscopy Not reported 1
Emery 2010 SIAscopy ≥6 1
Guitera RCM 2012 Not reported 1
Digital dermoscopy algorithms Multiple algorithms, different cut-offs 1
*Score = (A score×1.3)+(B score×0.1)+(C score×0.5)+(D score×0.5).
ABC, Asymmetry, irregular Borders, more than one or uneven distribution of Colour; ABCD, Asymmetry, irregular Borders, more than one or
uneven distribution of Colour, or a large (greater than 6 mm) Diameter; ABCDE, Asymmetry, irregular Borders, more than one or uneven
distribution of Colour, or a large (greater than 6mm) Diameter, Evolution of moles; AC, asymmetry, colour variation; CASH, color, architecture,
symmetry, and homogeneity; CPR, clinical prediction rules RCM, reflectance confocal microscopy.
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numbers of true positives, false positives, true negatives,
false negatives, sensitivity and speciﬁcity and their corre-
sponding 95% CIs. Where sensitivity/speciﬁcity for more
than one observer was reported, the mean value was
included in the analysis. Studies were grouped for ana-
lysis by CPR type (ie, clinical or dermoscopic). Summary
estimates of sensitivity and speciﬁcity and their corre-
sponding 95% CIs were calculated using the bivariate
random effects model (midas). The bivariate model has
the beneﬁts of being easily interpretable, is technically
straightforward to undertake and takes into account the
sample and heterogeneity beyond chance between
studies.23
Individual and summary estimates of sensitivity and
speciﬁcity were plotted on a hierarchical summary
receiver operating characteristic (HSROC) graph. This
approach incorporates sensitivity and speciﬁcity, while
taking into account the correlation between the two.24
Sensitivity (true positive) was graphed on the y-axis and
1-speciﬁcity (false negative) on the x-axis. The 95% con-
ﬁdence region and the 95% prediction region were also
plotted around the pooled estimates in order to depict
the precision with which the pooled estimates were
determined (conﬁdence ellipse around the mean value)
and to illustrate the amount of between-study variation
(prediction ellipse).
RESULTS
Study selection
The search strategy yielded a total of 25 816 articles. Of
these 9481 were duplicates and 16 166 were deemed
irrelevant based on title/abstract. The remaining 171
were reviewed in full with 51 meeting the inclusion cri-
teria (see online supplementary appendix 2). From
these, 24 unique melanoma CPRs were identiﬁed
(table 1). Twelve papers reported derivation and valid-
ation studies, 36 were validation studies only and three
were impact analyses.
Summary of studies
Table 2 summarises the characteristics of the included
studies. The majority (11, 22%) were conducted in
Italy14 15 25–34 and ranged from an analysis of 40 lesions
to 1580 lesions. From 13 studies providing information,
mean age of included patients ranged from 36.7 to
53.25 28 31 35–44 From the 14 studies that reported
gender, the proportion of males ranged from 22% to
60%.25 31 33 35–45 In total, 31 of the 50 studies were pub-
lished in/or after 2000.14 25 28 29 31–37 42–44 46–62 Five
studies were set in primary care,36 44 49 62 63 with the
remainder undertaken in specialist outpatient settings.
Summary of CPRs identified
Of the 24 rules identiﬁed, four were clinical (ie, naked
eye), 17 were dermoscopic and the remaining three
used novel diagnostic technologies. The most commonly
applied clinical CPR was the ABCDE rule (ﬁve
studies),6 15 28 64 65 while for dermoscopy the most
common were the Asymmetry, irregular Borders, more
than one or uneven distribution of Colour, or a large
(greater than 6 mm) Diameter (ABCD) rule of dermo-
scopy (23 studies)14 25 26 29 31 32 39 42 43 47–49 52 53 57 65–70
and the 7-point checklist for dermoscopy (17
studies).14 25 26 29 35 37 42 43 46–50 52 56 57 59
Each of the elements included in the 24 rules identi-
ﬁed are presented in table 3. All four clinical rules
included the elements of diameter and colour variega-
tion (table 3 and see online supplementary appendix 1).
The most frequently included elements in the 17 dermo-
scopic rules were multiple colours (13 rules), asymmetry
(12 rules) and streaks (10 rules) (table 3 and see online
supplementary appendix 1).
Methodological quality of validation studies
Based on the CHARMS checklist, the quality of included
studies varied.21 All studies had weaknesses in study
design and quality assessment was often hindered by
poor reporting of methods. The studies had reasonable
sample sizes and all provided adequate deﬁnitions of the
outcome of interest. However, a number of important
weaknesses were identiﬁed. None of the studies reported
on missing data and key performance measures of model
performance (eg, calibration) were often missing.
Derivation studies typically reported information on
model development, in terms of selection of candidate
predictors, selection of predictors during modelling, and
model evaluation. However, often the methods applied
introduced a strong risk of bias, for example, a number
of studies described splitting the original sample into a
development and validation sample which is considered
statistically inefﬁcient and results in overﬁtting of the
model.21 Full results of the quality assessment are shown
in online supplementary appendix 3.
Predictive accuracy of melanoma CPRs
The results for the most commonly applied CPRs, the
ABCD rule and the 7-point checklist are presented here.
The sensitivity and speciﬁcity of all rules identiﬁed
(including the ABCDE clinical rule, the seven features
for melanoma rule and Menzies dermoscopy for melan-
oma rule) are summarised in table 4.
Clinical (naked eye) CPRs for melanoma diagnosis
Four studies validating the ABCDE clinical rule6 15 28 64
and one validating the ABCD clinical rule65 were
included. There was insufﬁcient data to conduct any
meta-analysis. Rao et al reported a sensitivity of 0.84 and
speciﬁcity of 0.78, for an unspeciﬁed cut-point.65
Six studies validating the original and revised 7-point
checklist were included. There was insufﬁcient data to
conduct a meta-analysis. Of the four studies validating
the original 7-point checklist (cut-point ≥3), three
reported sensitivity (range 0.44–0.86, mean 0.70) and
speciﬁcity (range 0.62–0.94, mean 0.74).40 41 44 Only
one of the four studies validating the revised 7-point
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Table 2 Characteristics of validation and impact analysis studies included
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Annessi
2007,25 Italy
Department of
dermatology
ABCD rule of
dermoscopy
7-point checklist
for dermoscopy
198
96 melanomas, 102
non-melanoma
N=195
54% male
Mean age: 43
2
ELM-experienced
dermatologists
ABCD rule of dermoscopy
(cut-point ≥4.75)
Se: 84.4
Sp: 74.5
7-point checklist for
dermoscopy (cut-point ≥3)
Se: 78.1
Sp: 64.7
Argenziano
1998,26 Italy
Department of
dermatology
7-point checklist
for dermoscopy
ABCD rule of
dermoscopy
342
117 melanoma, 225
non-melanoma
NR 5
3 experienced
2 less experienced
7-point checklist for
dermoscopy (cut-point ≥3)
Expert user:
Se: 95.0
Sp: 75.0
Non-expert user (mean):
Se: 89.0
Sp: 61.5
ABCD rule of dermoscopy
(cut-point ≥4.75)
Expert user:
Se: 85.0
Sp: 66.0
Non-expert user (mean):
Se: 91.5
Sp: 31.0
Argenziano
2003,14 9
countries
Department of
dermatology
ABCD rule of
dermoscopy
7-point checklist
for dermoscopy
Menzies 1996
dermoscopy for
melanoma
108 NR 40
Experienced
ABCD rule of dermoscopy
(cut-point ≥4.75)
Se: 82.6
Sp: 70.0
7-point checklist for
dermoscopy
Se: 85.7
Sp: 71.1
Menzies 1996 dermoscopy
for melanoma
Se: 85.7
Sp: 71.1
Continued
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Table 2 Continued
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Argenziano
2011,27 Italy
Department of
dermatology
7-point checklist
for dermoscopy
Revised 7-point
checklist for
dermoscopy
300
100 excised melanoma,
100 excised
non-melanoma, 100
non-excised
non-melanoma
NR 8
Experienced
7-point checklist for
dermoscopy (cut-point ≥3)
Se: 77.9
Sp: 85.6
Revised 7-point checklist for
dermoscopy (cut-point ≥1)
Se: 87.8
Sp: 74.5
Benelli
1999,15 Italy
Department of
dermatology
7FFM (seven
features for
melanoma)
dermoscopy
ABCDE clinical
rule
401
60 melanomas, 341
non-melanoma
NR 2
Research team
7FFM (seven features for
melanoma) dermoscopy
(cut-point of ≥2)
Se: 80.0
Sp: 89.1
ABCDE clinical rule
(cut-point ≥2)
Se: 85.0
Sp: 44.5
Benelli
2000,28 Italy
Department of
dermatology
7FFM (seven
features for
melanoma)
dermoscopy
ABCDE clinical
rule
600
76 melanomas, 524
non-melanoma
Mean age: 53 3 7FFM (seven features for
melanoma) dermoscopy
(cut-point of ≥2)
Se: 68.8
Sp: 86.0
ABCDE clinical rule (cut-point
of ≥2)
Se: 47.3
Sp: 56.0
Binder
1999,66
Austria
Department of
dermatology
ABCD rule of
dermoscopy
250 NR 17
12 experienced
5 trainee
ABCD rule of dermoscopy
(cut-point ≥4.75)
Se: 81.0
Sp: 77.0
ABCD rule of dermoscopy
(cut-point ≥5.45)
Se: 73.0
Sp: 90.0
Blum 2003,71
Germany
Department of
dermatology
The 3-colour
dermoscopy test
249 NR NR The 3-colour dermoscopy test
Se: 76.9
Sp: 90.1
Continued
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Table 2 Continued
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Blum 2004,47
Germany
Department of
dermatology
ABCD rule of
dermoscopy
7-point checklist
for dermoscopy
Menzies 1996
dermoscopy for
melanoma
Simplified
ABC-point list for
dermoscopy
7FFM (seven
features for
melanoma)
dermoscopy
269
84 melanomas, 185
non-melanoma
NR NR ABCD rule of dermoscopy
Se: 90.5
Sp: 72.4
7-point checklist for
dermoscopy
Se: 90.5
Sp: 87.0
Menzies 1996 dermoscopy
for melanoma
Se: 95.2
Sp: 77.8
7FFM (seven features for
melanoma) dermoscopy
Se: 94.0
Sp: 74.6
Simplified ABC-point list for
dermoscopy
Se: 90.5
Sp: 87.0
Blum 2004,48
Germany
Department of
dermatology
ABCD rule of
dermoscopy
7-point checklist
for dermoscopy
Menzies 1996
dermoscopy for
melanoma
7FFM (seven
features for
melanoma)
dermoscopy
269
84 melanomas, 185
non-melanoma
NR NR ABCD rule of dermoscopy
Se: 90.5
Sp: 72.4
7-point checklist for
dermoscopy
Se: 90.5
Sp: 87.0
Menzies 1996 dermoscopy
for melanoma
Se: 95.2
Sp: 77.8
7FFM (seven features for
melanoma) dermoscopy
Se: 94.0
Sp: 74.6
Buhl 2012,35
Germany
Department of
dermatology
DynaMel Algorithm
7-point checklist
for dermoscopy
675 N=688
57% male
Mean age: 42
Dermatology residents DynaMel Algorithm
Se: 77.1
Sp: 98.1
7-point checklist for
dermoscopy (cut-point ≥3)
Se: 47.5
Sp: 99.0
Continued
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Table 2 Continued
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Carli 2002,29
Italy
Department of
dermatology
ABCD rule of
dermoscopy
7-point checklist
for dermoscopy
200
44 melanomas, 156
non-melanoma
NR 5
Dermatology residents
ABCD rule of dermoscopy
(cut-point ≥5.45)
Se: 88.1
Sp: 45.7
7-point checklist for
dermoscopy (cut-point ≥3)
Se: 91.9
Sp: 35.2
Dal Pozzo
1999,30 Italy
Department of
dermatology
7FFM (seven
features for
melanoma)
dermoscopy
713
168 melanomas, 545
non-melanoma
NR 3 7FFM (seven features for
melanoma) dermoscopy
Se: 94.6
Sp: 85.5
Dolianitis
2005,49
Australia
Primary care
and dermatology
department
7-point checklist
for dermoscopy
ABCD rule of
dermoscopy
Menzies 1996
dermoscopy for
melanoma
40
20 melanomas, 20
non-melanoma
NR 61
35 primary care
physicians, 10
dermatologists, 16
trainee dermatologists
7-point checklist for
dermoscopy
Se: 81.4
Sp: 73.0
ABCD rule of dermoscopy
(cut-point ≥5.45)
Se: 77.5
Sp: 80.4
Menzies 1996 dermoscopy
for melanoma
Se: 84.6
Sp: 77.7
Emery
2010,36 UK
Family practice Emery 2010
SIAscopy in
primary care for
melanoma
1211 N=858
52% male
Mean age: 50
1
SIAscopy expert
Emery 2010 SIAscopy in
primary care for melanoma
Se: 50.0
Sp: 84.0
Feldman
1998,67
Austria
Department of
dermatology
ABCD rule of
dermoscopy
500
30 melanomas, 470
non-melanoma
NR NR ABCD rule of dermoscopy
(cut-point ≥4.2)
Se: 88.0
Sp: 64.0
Gereli 2010,50
Turkey
Department of
dermatology
7-point checklist
for dermoscopy
3-point checklist
for dermoscopy
96
48 melanoma, 48
non-melanoma
NR 3
2 experienced
1 inexperienced
7-point checklist for
dermoscopy (cut-point ≥3)
Se: 87.5
Sp: 16.2
3-point checklist for
dermoscopy (cut-point ≥2)
Se: 89.6
Sp: 31.2
Continued
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Table 2 Continued
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Guitera
2012,51
Multiple
Skin cancer
clinic
Guitera 2012
confocal
microscopy for
melanoma
710
216 melanomas, 494
non-melanoma
N=663 NR Guitera 2012 confocal
microscopy for melanoma
Se: 87.6
Sp: 70.8
Haenssle
2010,37
Germany
Department of
dermatology
7-point checklist
for dermoscopy
1219
127 melanomas, 1092
non-melanoma
N=688
57% male
Mean age: 42
Inexperienced 7-point checklist for
dermoscopy (cut-point ≥3)
Se: 62.0
Sp: 97.0
Healsmith
1993,64 UK
Pigmented
lesion clinic
Revised 7-point
checklist (clinical)
ABCDE clinical
rule
165
65 melanoma, 100
non-melanoma
NR NR Revised 7-point checklist
(clinical)
Se: 100
Sp: NR
ABCDE clinical rule
Se: 92.3
Sp: NR
Henning
2008,52 USA
Department of
dermatology
CASH
dermoscopy
algorithm
ABCD rule of
dermoscopy
7-point checklist
for dermoscopy
Menzies 1996
dermoscopy for
melanoma
150
50 melanoma, 100
non-melanoma
NR 2
Inexperienced
CASH dermoscopy algorithm
Se: 87.0
Sp: 67.0
ABCD rule of dermoscopy
Se: 86.0
Sp: 74.0
7-point checklist for
dermoscopy
Se: 76.0
Sp: 57.0
Menzies 1996 dermoscopy
for melanoma
Se: 92.0
Sp: 38
Higgins
1992,38 UK
Department of
dermatology
7-point checklist
(clinical)
7-point checklist
(clinical) revised
100
0 melanoma, 100
non-melanoma
N=100
30% male
Mean age: 36.7
NR 7-point checklist (clinical)
revised
Se: NR
Sp: 70.0
Kittler 1999,39
Austria
Department of
dermatology
ABCD rule of
dermoscopy
ABCDE rule
(dermoscopy)
356
73 melanomas, 283
non-melanoma
N=352
43% male
Mean age: 52
NR NR
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Table 2 Continued
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Keefe 1989,40
Scotland
Hospital
dermatology
clinic
7-point checklist
(clinical)
222 N=195
22% male
Mean age: 43
Dermatologists
195 patients
7-point checklist (clinical)
(cut-point ≥3)
Dermatologists:
Se: 85.7
Sp: 66.5
Patients:
Se: 71.4
Sp: 66.2
Kreusch
1992,84
Germany
Department of
dermatology
Kreusch 1992
dermoscopy for
melanoma
317
96 melanomas, 221
non-melanoma
NR 2
1 experienced
1 inexperienced
Kreusch 1992 dermoscopy for
melanoma
Experienced:
Se: 98.9
Sp: 94.1
Inexperienced:
Se: 97.0
Sp: 94.2
Lorentzen
1999,68
Denmark
Department of
dermatology
ABCD rule of
dermoscopy
232 NR 8
4 experienced
4 inexperienced
ABCD rule of dermoscopy
(cut-point ≥4.75)
Se: 59.0
Sp: 92.0
ABCD rule of dermoscopy
(cut-point ≥5.45)
Se: 41.0
Sp: 98.0
Lorentzen
2000,53
Denmark
Department of
dermatology
ABCD rule of
dermoscopy
258
64 melanoma, 194
non-melanoma
NR 3
Experienced
ABCD rule of dermoscopy
(cut-point ≥4.75)
Se: 70.7
Sp: 88.0
Luttrell
2012,54
Austria
Department of
dermatology
AC rule for
dermoscopy
200
25 melanoma, 178
non-melanoma
NR 17
Lay persons
AC rule for dermoscopy
Se: 91.2
Sp: 94.0
Mackie
2002,55
Scotland
Pigmented
lesion clinic
The 3-colour
dermoscopy test
126
69 melanoma 57
non-melanoma
NR 3
Experienced
The 3-colour dermoscopy test
Se: 97.0
Sp: 55.0
McGovern
1992,41 USA
Dermatology
clinic
7-point checklist
(clinical)
ABCD clinical rule
237
16 malignant, 221
non-melanoma
N=179
50% male
Mean age: 44
NR 7-point checklist (clinical)
Se: 0.44
Sp: 0.94
Menzies
1996,85
Australia
Melanoma unit Menzies 1996
dermoscopy for
melanoma
385
107 melanomas
NR NR Menzies 1996 dermoscopy
for melanoma
Se: 92.0
Sp: 71.0
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Table 2 Continued
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Menzies
200856
7-point checklist
for dermoscopy
3-point checklist of
dermoscopy
Menzies 1996
dermoscopy for
melanoma
Menzies 2008
dermoscopy for
melanoma
Menzies 2008
dermoscopy for
skin cancer
497
105 melanomas, 392
non-melanoma
NR 12
Experienced
7-point checklist for
dermoscopy
Se: 41.0
Sp: 83.0
3-point checklist of
dermoscopy
Se: 50.0
Sp: 71.0
Menzies 1996 dermoscopy
for melanoma
Se: 54.0
Sp: 76.0
Menzies 2008 dermoscopy
for melanoma
Se: 70.0
Sp: 56.0
Menzies 2008 dermoscopy
for skin cancer
Se: 95.0
Sp: 80.0
Menzies
201357
ABCD rule of
dermoscopy
7-point checklist
for dermoscopy
3-point checklist of
dermoscopy
Menzies 1996
dermoscopy for
melanoma
CASH
dermoscopy
algorithm
Menzies 2013
dermoscopy for
nodular melanoma
465
217 melanomas, 248
non-melanoma
NR 12 ABCD rule of dermoscopy
Se: 81.5
Sp: NR
7-point checklist for
dermoscopy
Se: 94.4
Sp: NR
3-point checklist of
dermoscopy
Se: 83.9
Sp: NR
Menzies 1996 dermoscopy
for melanoma
Se: 98.4
Sp: NR
CASH dermoscopy algorithm
Se: 41.0
Sp: 83.0
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Table 2 Continued
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Menzies 2013 dermoscopy
for nodular melanoma
Se: 93.0
Sp: 70.0
Nachbar
1994,69
Germany
Department of
dermatology
ABCD rule of
dermoscopy
194
69 melanomas
NR NR ABCD rule of dermoscopy
(cut-point ≥5.45)
Se: 92.8
Sp: 91.2
Nilles 1994,86
Germany
Department of
dermatology
Nilles 1994
dermoscopy for
melanoma
260
72 melanomas, 188
non-melanoma
NR NR Nilles 1994 dermoscopy for
melanoma
Se: 90.0
Sp: 85.0
Osborne
1999,45 UK
Department of
Dermatology
Revised 7-Point
Checklist (clinical)
778
778 melanomas, 0
non-melanoma
N=733
35% male
NR Revised 7-Point Checklist
(clinical)
False negative rate: 18.5
Piccolo
2014,31 Italy
Department of
dermatology
ABCD rule of
dermoscopy
165
33 melanomas, 129
non-melanoma
N=165
59% male
Mean age: 43.5
4
3 dermatologists 1 FP
ABCD rule of dermoscopy
Se: 91.0
Sp: 52.0
Pizzichetta
2002,32 Italy
Department of
oncology
ABCD rule of
dermoscopy
129 N=123 2
Experienced
ABCD rule of dermoscopy
(cut-point ≥4.75)
Se: 90.0
Sp: 43.0
ABCD rule of dermoscopy
(cut-point ≥5.45)
Se: 90.0
Sp: 53.5
Rao 199765 Department of
dermatology
ABCD rule of
dermoscopy
ABCD clinical rule
73 N=63 4
Experienced
dermatologists
ABCD rule of dermoscopy
(cut-point ≥4.75)
Se: 90.0
Sp: 57.0
ABCD clinical rule
Se: 84.0
Sp: 78.0
Skvara
2005,42
Austria
Department of
dermatology
ABCD rule of
dermoscopy
7-point checklist
for dermoscopy
325
63 melanomas, 262
non-melanoma
N=297
44% male
Mean age: 39
2
Experienced
dermatologists
ABCD rule of dermoscopy
(cut-point ≥4.75)
Se: 31.7
Sp: 87.3
7-point checklist for
dermoscopy
Se: 11.1
Sp: 95.2
Continued
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Table 2 Continued
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Soyer 2004,33
Italy
Department of
dermatology
3-point checklist of
dermoscopy
231
68 melanomas, 163
non-melanomas
N=225
49% male
6
Inexperienced
3-point checklist of
dermoscopy
Se: 96.3
Sp: 32.8
Stolz 1994,70
Germany
Department of
dermatology
ABCD rule of
dermoscopy
157 NR NR ABCD rule of dermoscopy
(cut-point ≥5.45)
Se: 97.9
Sp: 90.3
Strumia
2003,34 Italy
Department of
dermatology
ABCD rule of
dermoscopy
ABCDE rule
(dermoscopy)
49 NR 2
Thomas
1998,6 France
Department of
dermatology
ABCDE clinical
rule
1140 NR NR ABCDE clinical rule
(cut-point ≥2)
Se: 89.3
Sp: 65.3
Unlu 2014,43
Turkey
Department of
dermatology
ABCD rule of
dermoscopy
7-point checklist
for dermoscopy
3-point checklist of
dermoscopy
CASH
dermoscopy
algorithm
115
24 melanomas, 91
non-melanoma
N=115
49% male
Mean age: 39
3
Experienced
dermatoscopists
ABCD rule of dermoscopy
Se: 91.6
Sp: 60.4
7-point checklist for
dermoscopy
Se: 79.1
Sp: 62.6
3-point checklist of
dermoscopy
Se: 87.5
Sp: 65.9
CASH dermoscopy algorithm
Se: 91.6
Sp: 64.8
Wadhawan
2011,59 USA
Images from
library of skin
cancer
7-point checklist
for dermoscopy
347 NR NR 7-point checklist for
dermoscopy
Se: 87.3
Sp: 71.3
Walter 2013,44
UK
Family practice 7-point checklist
(clinical)
Revised 7-point
checklist (clinical)
1436
36 melanomas, 1400
non-melanoma
N=1182
35.9% male
Mean age: 44.7
NR 7-point checklist (clinical)
Se: 80.6
Sp: 61.7
Revised 7-point checklist
(clinical)
Se: 91.7
Sp: 33.1
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Table 2 Continued
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Zalaudek
2006,60 29
Countries
Pigmented
lesion clinic
3-point checklist
for dermoscopy
150
44 malignant, 106
non-melanoma
NR 150
Varying levels of
experience
3-point checklist for
dermoscopy
Se: 94.0
Sp: 71.9
Impact Analysis Studies
Author year,
Country
Study design Participant
selection
Lesions Intervention Control Outcomes
Westerhoff
2000,62
Australia
Primary care
Controlled before
and after
74 FPs n=100 (50 melanoma, 50
non-melanoma)
Selected randomly from
the Sydney Melanoma
Unit image database
Educational intervention. FPs
given educational material on
Menzies 1996 rule, followed by
a 1-hour
Presentation on surface
microscopy
Usual care Correct diagnosis of
melanoma, percent (SD):
Intervention 75.9 (12)
Control 54.8 (22)
Correct diagnosis of
non-melanoma, percent (SD):
Intervention 57.8 (14)
Control 55.8(15)
Walter 2012,63
England
Primary care
RCT 15 FP practices 1580 from 1297 patients Patients assessed using the
MoleMate system (SIAscopy
with primary care scoring
algorithm)
Best practice (clinical
history, naked eye
examination, 7-checklist
clinical)
Primary, appropriateness of
referral (defined as the
proportion of referred lesions
that secondary care experts
decided to biopsy or monitor):
no statistically significant
difference between
intervention and control;
56.8% vs 64.5%; difference
−8.1% (95% CI −18.0% to
1.8%).
Secondary:
Appropriate management of
benign lesions in primary
care: no statistically significant
difference between
intervention and control
(99.6% vs 99.2%, p=0.46).
Agreement with an expert
decision to biopsy or monitor:
no statistically significant
difference between
intervention and control
(98.5% vs control 95.7%,
p=0.26).
Continued
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Table 2 Continued
Validation studies
Author year,
country Setting CPR used Lesions
Patient: n, sex,
mean age
CPR applied by: n
Experience
Reported sensitivity/
specificity
Patient satisfaction: more
intervention patients ranked
their consultation very good/
excellent for thoroughness
than control (83.1% vs 71.2%,
p<0.001).
Patient anxiety: no statistically
significant difference between
intervention and control in
anxiety scores (32.56 vs
34.72, p=0.013)
Argenziano
2006,72 Spain,
Italy
Primary Care
RCT 73 FPs 2548 lesions from 2522
patients presenting to
primary care with a
pigmented skin lesion.
1203 lesions in
dermoscopy group (six
melanoma)
1345 lesions in control
group (six melanoma)
Use of dermoscopy in addition
to ‘naked-eye’ lesion
screening.
Both groups received a
4 hours educational
intervention incorporating
clinical examination and use of
the 3-point checklist
(dermoscopy algorithm)
Naked-eye screening
alone.
Primary outcome:
Referral accuracy of PCPs
(defined as the ability of the
PCP to correctly determine a
lesion may be malignant or
benign, when the gold
standard is diagnosis by a
second expert clinician)
reported as sensitivity,
specificity, PPV, NPV.
Significant difference in
sensitivity (dermoscopy
79.2%, naked eye 54.1%,
p=0.002) and negative
predictive value (dermoscopy
9801%, naked eye 95.8%,
p=0.004)
Secondary outcome:
Number of malignant tumours
missed by PCPs using
naked-eye examination
(n=23) and using dermoscopy
(n=6) (p=0.002)
ABC, Asymmetry, irregular Borders, more than one or uneven distribution of Color; ABCD, Asymmetry, irregular Borders, more than one or uneven distribution of Colour, or a large (greater than
6 mm) Diameter; ABCDE, Asymmetry, irregular Borders, more than one or uneven distribution of Colour, or a large (greater than 6mm) Diameter, Evolution of moles; AC, asymmetry, colour
variation; CASH, colour, architecture, symmetry, and homogeneity; CPR, clinical prediction rules, ELM, epiluminescence microscopy; FP, family physicians; PCP, primary care physicians; PPV,
positive predictive value; NPV, negative predictive value; NR, Not reported; RCT, randomised controlled trials; Se, sensitivity; Sp, specificity.
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Table 3 Comparison of elements in clinical prediction rules for malignant melanoma
(a) Clinical rules
Clinical CPR name
Elements ABCD ABCDE 7-point checklist Revised 7-point checklist
Asymmetry X X X
Border irregularity X X X
Colour variegation X X X X
Diameter (>6 mm) X X X (>7 mm) X (>7 mm)
Evolving (eg, size, shape, colour) X X (size) X
Altered sensation X X
Inflammation X X
Crusting, bleeding X X
Cut-point ≥1 ≥1 or ≥2 ≥3 ≥3
(b) Dermoscopic rules
CPR name
Element ABCD
7-point
checklist
Revised
7-point
checklist
Menzies
1996
3-point
checklist 7FFM CASH ABCDE
3-colour
test
Kreusch
1992
Nilles
1994
Menzies
2008—
melanoma
Menzies
2008—
skin
cancer DynaMel
Simplified
ABC AC rule
Asymmetry X X X X X X X X X X X X
Multiple colours (light/dark
brown, black, red, white, blue)
X X X X X X X X X X X X X
Architectural disorder (structures
and colours)
X X X X X X X X
Atypical network X X X X X X X X X
Blue-white veil X X X X X X
Blue-white structures X X
Streaks/radial streaming/
pseudopods
X X X X X X X X X X
Dots, globules X X X X X X X X X
Regression structures or
erythema
X X X X X X X X
Scarring X X
Blotches (structure less region
>10%
X X X
Atypical vascular pattern X X X X X X X
Recognisable as benign X
Abrupt cut-off border pigment X X X X
Blue-grey dots X
Change X X X X
Cut-point ≥4.75
≥5.45
≥3 ≥1 ≥1, no
features
≥1 ≥2 ≥2 Not
reported
≥3 Not
reported
Not
reported
≥1 ≥0 (high
sensitivity)
≥1 (high
specificity)
≥3 ≥4 Not
reported
ABC, Asymmetry, irregular Borders, more than one or uneven distribution of Colour; ABCD, Asymmetry, irregular Borders, more than one or uneven distribution of Colour, or a large (greater
than 6 mm) Diameter; ABCDE, Asymmetry, irregular Borders, more than one or uneven distribution of Colour, or a large (greater than 6mm)Diameter, Evolution of moles; AC, asymmetry, colour
variation; CASH, color, architecture, symmetry, and homogeneity; CPR, clinical prediction rules; FFM, features for melanoma.
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checklist (cut-point ≥1) reported sensitivity (0.92) and
speciﬁcity (0.33) (table 4).44
Dermoscopic CPRs for melanoma diagnosis
ABCD rule of dermoscopy
The ABCD rule of dermoscopy (also described as the
ABCD rule of Stolz), was validated in 23 studies, 15 of
which applied a cut-point of >4.75 (indicating a suspi-
cious lesion) and six studies a cut-point of 5.45 (highly
suggestive for melanoma). At a cut-point of >4.75, eight
studies provided sufﬁcient information for
meta-analysis,42 43 47 52 65 71 resulting in a pooled sensi-
tivity of 0.85 (95% CI 0.73 to 0.93) and speciﬁcity of
0.72 (95% CI 0.65 to 0.78) (ﬁgure 1A, B). This indicates
that at this cut-point, the dermoscopy CPR is more
useful for ruling out rather than ruling in melanoma,
with a higher pooled sensitivity than speciﬁcity. I2 were
high (>70%), indicating a high degree of heterogeneity.
Of the seven studies excluded from meta-analysis, sensi-
tivity ranged from 0.71 to 0.91 (mean 0.79) and speciﬁ-
city ranged from 0.43 to 0.92 (mean 0.72). None of the
six studies that applied a cut-point of 5.45 were suitable
for meta-analysis. From four studies that presented the
information, sensitivity ranged from 0.73 to 0.98 (mean
0.85) and speciﬁcity ranged from 0.46 to 0.91 (mean
0.79) (table 4).
Table 4 Sensitivity and specificity of all clinical and dermoscopy CPRs
Rule name Cut-point Sensitivity* Specificity*
Clinical rules
ABCDE ≥1 Two studies
0.47–0.92 (mean 0.70)
One study
0.56
≥2 0.85 0.44
7-point checklist ≥3 Three studies
0.44–0.86 (mean 0.70)
Three studies
0.62–0.94 (mean 0.74)
Revised 7-point checklist ≥3 0.92 0.33
ABCD rule ≥1 0.84 0.78
Dermoscopic rules
ABCD rule ≥4.75 Meta-analysis (eight studies)
0.85 (95% CI 0.73 to 0.93)
Meta-analysis (eight studies)
0.72 (95% CI 0.65 to 0.78)
≥5.45 Four studies
0.73–0.98 (mean 0.85)
Four studies
0.46–0.91 (mean 0.79)
≥4.2 0.88 0.64
7-point checklist ≥3 Meta-analysis (11 studies)
0.77 (95% CI 0.61 to 0.88)
Meta-analysis (11 studies)
0.80 (95% CI 0.59 to 0.92)
Menzies 1996 for melanoma ≥1 Six studies
0.85–0.95 (mean 0.91)
Six studies
0.38–0.78 (mean 0.69)
3-point checklist ≥1 Five studies
0.50–0.96 (mean 0.84)
Four studies
0.31–0.72 (mean 0.55)
Seven features for melanoma (7FFM) ≥2 Five studies
0.69–0.95 (mean 0.86)
Five studies
0.74–0.86 (mean 0.82)
CASH algorithm ≥8 Three studies
0.41–0.92 (mean 0.73)
Three studies
0.65–0.97 (mean 0.82)
The 3-colour test ≥3 Two studies
0.77–0.97 (mean 0.87)
Two studies
0.55–0.90 (mean 0.73)
Revised 7-point checklist ≥1 0.88 0.28
Kreusch 1992 Not reported 0.99 0.94
Nilles 1994 Not reported 0.90 0.85
Menzies 2008 for melanoma ≥1 0.70 0.56
DynaMel algorithm ≥3 0.77 0.98
Menzies 2008 for skin cancer ≥0 (high sensitivity);
≥1 (high specificity)
0.95 0.80
Simplified ABC-point list ≥4 0.90 0.87
AC rule Not reported 0.91 0.94
Emery 2010 SIAscopy ≥6 0.50 0.84
Guitera RCM 2012 Not reported 0.88 0.71
ABCDE rule Not reported Not reported Not reported
*Where sensitivity and specificity are presented for more than one study, the range and mean are presented. Where meta-analysis was
possible, values from meta-analysis are presented with 95% CIs.
ABC, Asymmetry, irregular Borders, more than one or uneven distribution of Colour; ABCD, Asymmetry, irregular Borders, more than one or
uneven distribution of Colour, or a large (greater than 6 mm) Diameter; ABCDE, Asymmetry, irregular Borders, more than one or uneven
distribution of Color, or a large (greater than 6mm) Diameter, Evolution of moles; AC, asymmetry, colour variation; CASH, color, architecture,
symmetry, and homogeneity; CPR, clinical prediction rules; RCM, reflectance confocal microscopy.
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Seven-point checklist for dermoscopy
The 7-point checklist for dermoscopy was validated in 18
studies, 17 of which applied a cut-point of 3. 11 studies
provided sufﬁcient information for meta-analysis, reveal-
ing a pooled sensitivity of 0.77 (95% CI 0.61 to 0.88)
and pooled speciﬁcity of 0.80 (95% CI 0.59 to 0.92)
(See ﬁgure 2A, B).25–27 35 37 42 43 47 50 52 71 There was a
high degree of heterogeneity in the results (I2>90%).
Removing two outliers27 50 made minimal difference to
the pooled result. Only one study validated the revised
7-point checklist for dermoscopy and reported sensitivity
0.78 and speciﬁcity 0.65 for a cut-point of 3 (table 4).27
Impact analysis
We identiﬁed three unique studies that examined the
impact of a melanoma CPR on processes of care (melan-
oma diagnosis and referrals), however, no patient out-
comes were examined (table 2).62 63 The
methodological quality of these studies is presented in
online supplementary appendix 4.
Using a controlled before–after design, Westerhoff
et al investigated the impact of an educational interven-
tion about the Menzies 1996 rule on melanoma diagno-
sis by family physicians (FP). The control group did not
receive the training. Postintervention, there was a signiﬁ-
cant improvement in melanoma diagnosis (75.9% vs
62.7%, p<0.001). No signiﬁcant improvement was seen
in the control group (54.8% vs 53.7%, p=0.59).62
Walter et al conducted a RCT to compare the use of a
new imaging device, the MoleMate system (SIAscopy
with a primary care scoring algorithm), to current best
practice (clinical history, naked-eye examination, 7-point
checklist). The authors found no difference between
these two approaches in terms of appropriate referrals
(the proportion of referred lesions that secondary care
experts biopsied or monitored) to urgent skin cancer
clinics (intervention 56.8% vs control 64.5% p=0.11) or
the proportion of benign lesions appropriately managed
in primary care (intervention 99.6% vs control 99.2%,
p=0.46).63
Argenziano et al’s RCT,72 involved primary care physi-
cians ﬁrst attending a 1-day training course describing the
ABCD rule (cut-point unspeciﬁed) and the 3-point check-
list. They were then randomly assigned to assess patients
with skin lesions, either by clinical (ie, naked eye) examin-
ation, or by dermoscopy using the 3-point checklist. The
referral assessments were checked for accuracy by derma-
tologists. The dermoscopy arm demonstrated a 25%
improvement in the sensitivity of primary care referrals of
pigmented lesions compared with the naked-eye examin-
ation (79.2% vs 54.1%, p=0.002), without a reduction in
speciﬁcity (71.8% vs 71.3%, p=0.915).72
DISCUSSION
Summary of findings
This systematic review identiﬁed 48 studies validating a
total of 24 CPRs for melanoma. Overall, the majority of
validation studies used dermoscopic CPRs, with very few
studies validating clinical CPRs. Meta-analysis of the der-
moscopic CPRs demonstrated relatively high pooled esti-
mates of sensitivity (0.77–0.86). The clinical implication
is that applying dermoscopy CPRs will enable low-risk
Figure 1 (A) Diagnostic accuracy ABCD rule with dermoscopy—pooled sensitivity and specificity (eight studies). (B) Summary
receiver operating characteristic curves for ABCD rule of dermoscopy The circles represent individual studies and the size
reflects the sample size. The red square represents the summary estimates of sensitivity and specificity and the dotted ellipses
around this represent the 95% CI around the estimate. The 95% prediction region (amount of variation between studies) was
wide, suggesting heterogeneity between studies. ABCD, Asymmetry, irregular Borders, more than one or uneven distribution of
Colour, or a large (greater than 6 mm) Diameter; HSROC, hierarchical summary receiver operating characteristic.
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patients to be observed and kept under review in a
primary care setting, without immediate referral for exci-
sion to secondary care. Meta-analysis was not possible for
clinical CPRs but individual studies report variable sensi-
tivity, ranging from 0.44 to 0.86. Three impact analysis
studies were identiﬁed, with two reporting an improve-
ment in melanoma diagnosis with the use of a CPR.
Context of previous research
The sensitivities and speciﬁcities we report indicate that
currently available CPRs are reasonably good at ruling
out melanoma. The pooled sensitivity of the ABCD rule
for dermoscopy (cut-point of >4.75) was 0.85 (95% CI
0.73 to 0.93), higher than that of the 7-point checklist
for dermoscopy (0.77, 95% CI 0.61 to 0.88). While this
evidence would support the use of such rules in prioritis-
ing appropriate referrals for higher risk patients and
adopting a watchful waiting strategy in lower risk
patients, there are a number of important caveats that
may prevent their adoption in primary care.
Melanoma is a high-stakes condition, one which
doctors tend to be cautious in diagnosing, often prefer-
ring to excise a benign lesion rather than to miss a
potentially fatal cancer.73 In such cases, a CPR with near
perfect sensitivity would be desirable, however, it has
been argued that a lower sensitivity should not prevent
CPR use unless usual decisions, made without the rule,
are demonstrably better.74 Our results are comparable
with previous systematic reviews focused on melanoma
diagnosis across healthcare settings in highlighting that
dermoscopic CPRs are demonstrably better in terms of
diagnostic accuracy in comparison with inspection by
the naked eye.16 75 However, even a rule with almost
100% sensitivity may not be adopted. For instance,
implementation of the Canadian CT Head Rule, despite
100% sensitivity in validation studies, did not result in a
reduction in imaging rates, with clinicians’ reporting
unease with certain components of the rule and fear of
missing a high-stakes diagnosis as reasons for not adopt-
ing the CPR.76
Before considering whether to use a CPR in clinical
practice, it is essential that its performance be established
through external validation (ie, in settings outside where
it was derived). We identiﬁed a number of external valid-
ation studies in this review, however, in keeping with
much CPR research, the reporting of these studies was
often poor.77 78 In particular, the common issues of
limited acknowledgement and handling of missing data
and key performance measures of prediction models,
that is, calibration, being omitted was encountered.77
The lack of available data in some papers meant not all
studies could be combined in the meta-analysis, meaning
the sensitivities and speciﬁcities reported here are not
based on the totality of existing evidence. Furthermore,
we were unable to assess diagnostic accuracy at different
cut-point thresholds for respective CPRs. Improved
reporting of CPRs at cut-point thresholds will enable
pooling of diagnostic accuracy data, and will provide
more robust measures of diagnostic accuracy. After valid-
ation, impact analysis studies are undertaken to deter-
mine the impact of the implementation of a CPR on
processes and outcomes of care. Despite increasing
Figure 2 (A) Diagnostic accuracy of 7-point checklist with dermoscopy—pooled sensitivity and specificity (11 studies). (B)
Summary receiver operating characteristic curves for ABCD rule of dermoscopy The circles represent individual studies and the
size reflects the sample size. The red square represents the summary estimates of sensitivity and specificity and the dotted
ellipses around this represent the 95% CI around the estimate. The 95% prediction region (amount of variation between studies)
was wide, suggesting heterogeneity between studies. ABCD, Asymmetry, irregular Borders, more than one or uneven distribution
of Colour, or a large (greater than 6 mm) Diameter; HSROC, hierarchical summary receiver operating characteristic; ROC,
receiver operating characteristic.
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interest in developing and validating CPRs relevant to
primary care, relatively few have undergone impact ana-
lysis.79 Despite the large number of CPRs identiﬁed in
this review, we identiﬁed only three impact analysis
studies, with only two studies reporting an improvement
in correct melanoma diagnosis in primary care as a
result. Arguably, the dearth of well conducted and clearly
reported external validation and impact analysis studies
undermines trust in the use of such rules in practice.77
Current NICE guidelines for melanoma detection and
management recommend dermoscopy of any suspicious
lesion, advising against using computer-assisted diagnos-
tic tools (NG14) while promoting use of the weighted
7-point checklist in primary care to guide referral
(NG12).20 Based on the ﬁndings of this review, the
ABCD rule for dermoscopy had a higher sensitivity than
the seven point for dermoscopy checklist at their
respective cut-points, indicating its potential for use in
primary care. Dermoscopy, however, requires training
and equipment, and is less commonly performed in
primary care. Evidence suggests that dermatologists have
better diagnostic accuracy than primary care physi-
cians.18 Three studies retrieved in our search assessed
dermoscopy CPR performance when applied by non-
experts, with two studies reporting that the CPRs per-
formed well overall when used by non-experts, mainly
primary care physicians.49 66 72 Westerhoff et al62 and
Blum et al80 demonstrated that training primary care
physicians to use dermoscopy with CPRs showed signiﬁ-
cant improvement in the diagnosis of melanoma com-
pared with naked eye inspection. Alongside the use of
CPRs, training in dermoscopy would seem to be a strat-
egy that will enhance diagnostic accuracy of melanoma
in the future particularly in light of emerging evidence
of differences in dermoscopic features of melanoma
such as head and neck melanoma.81 It has also been
highlighted that signiﬁcant efforts are needed to stand-
ardise and improve dermoscopic terminology to more
broadly promote the use of dermoscopy in the primary
care setting.82 Of the 24 rules identiﬁed in this review,
four were clinical (ie, naked eye) and 17 were dermo-
scopic. Owing to the limited number of studies and
available data, no meta-analysis of clinical CPRs could be
conducted. The range of reported sensitivities from indi-
vidual studies indicates that there is insufﬁcient evidence
to recommend their use in practice.
Strengths and limitations of our study
The main strengths of this review are the use of broad
inclusion criteria, the systematic search of multiple data-
bases not limited by language, use of the CHARMS
checklist to assess methodological quality, pooling data
from a broad range of studies to enhance generalisabil-
ity and the use of a broad deﬁnition of primary care to
account for the variation in primary care services and
access internationally. However, the ﬁndings of this sys-
tematic review need to be interpreted in the context of
the limitations of the original studies. The lack of
available data in some papers meant not all studies
could be combined in the meta-analysis. A number of
studies that validated CPRs and algorithms using novel
diagnostic technologies which incorporated compu-
terised image analysis and artiﬁcial intelligence were
excluded from the review as routine use of these are not
currently recommended in UK NICE clinical guidelines.
Signiﬁcant heterogeneity existed between the studies
with respect to differences in the study populations and
application of the CPR. Finally, individual patient data
that enables pooling of risk scores at the different cut-
points would enable researchers to explore the clinical
use of applying risk scores at different cut-points with
the purpose of assessing the role of melanoma CPRs at
the different diagnostic thresholds of ‘ruling out’ (using
highest pooled sensitivity) or ‘ruling in’ (using highest
pooled speciﬁcity) of respective melanoma CPRs.
Implications for practice and future research
Early detection followed by curative surgery greatly
improves the prognosis of malignant melanoma. As the
incidence of melanoma skin cancer increases, primary
care physicians are increasingly required to screen for
melanoma.12 Therefore, efforts to increase the early
detection of melanoma must focus on supporting
primary care physicians in performing skin cancer
screenings with recent evidence highlighting the beneﬁts
of developing targeted screening strategies in high-risk
patients in primary care.18 83 This systematic review iden-
tiﬁed 24 separate clinical (naked eye) and dermoscopic
CPRs, with some overlap in the included the elements.
Our analysis highlights that dermoscopic CPRs have rea-
sonable sensitivity, with the ABCD rule for dermoscopy
having better sensitivity than the 7-point checklist for der-
moscopy. Further development of new rules is unlikely to
beneﬁt the ﬁeld of research. An increased emphasis on
better reporting of validation studies, particularly at dif-
ferent cut-point thresholds, would allow for the conduct
of more robust diagnostic accuracy meta-analysis to
inform decision making. Further methodologically
robust RCTs are necessary also to examine the impact of
implementing CPRs in clinical practice, in terms of
patient outcomes, physician behaviour, processes of care
and cost-effectiveness. Finally, while guidelines promote
the use of dermoscopy in the assessment of pigmented
skin lesions, there needs to be greater emphasis on train-
ing in primary care on this examination technique.
CONCLUSION
This systematic review and meta-analysis shows that der-
moscopic CPRs have reasonably high pooled estimates
of sensitivity and may be a useful tool for primary care
physicians prioritising appropriate referrals for higher
risk patients and adopting a watchful waiting strategy in
lower risk patients. The ABCD rule of dermoscopy has
higher pooled sensitivity than the 7-point checklist for
dermoscopy, when consideration about ruling out
20 Harrington E, et al. BMJ Open 2017;7:e014096. doi:10.1136/bmjopen-2016-014096
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melanoma is being made. A focus on impact analysis
may help translate melanoma CPRs into useful and
effective triage tools for use in primary care.
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